Basaksehir

Researchers are evaluating postoperative pain management methods in patients undergoing laparoscopic unilateral total extraperitoneal (TEP) herniorrhaphy, a common surgery for inguinal hernia repair. This prospective, randomized study compares the pain relief effects of two techniques: local anesthetic infiltration into the preperitoneal and surgical sites versus an ultrasound-guided bilateral transversus abdominis plane (TAP) block. The study also considers factors like hospital stay length and cost-effectiveness, aiming to identify the most beneficial approach for patient comfort and recovery. Sixty patients will be randomly assigned to two groups. Group I will receive bupivacaine injected into the preperitoneal space and each trocar incision during surgery. Group II will receive an ultrasound-guided bilateral TAP block by an anesthesiologist before waking from surgery, involving controlled injections of bupivacaine between specific abdominal muscle layers. Both groups receive standard multimodal pain management including paracetamol and NSAIDs, with intravenous paracetamol available as rescue analgesia. Participants will be monitored using the visual analog scale (VAS) to assess pain scores within 24 hours after surgery. Researchers will record demographics, anesthesia risk scores, comorbidities, operation time, additional analgesic use, and hospital stay duration. Safety and effectiveness will be evaluated through statistical analysis, with the goal of determining which method better controls postoperative pain and improves patient outcomes after laparoscopic hernia repair.

Deviated nasal septum is a common cause of nasal blockage that can lead to breathing difficulties and is linked to sleep problems like snoring and obstructive sleep apnea syndrome (OSAS). This research aims to find out how often difficult airway situations occur during septoplasty surgery, which corrects a deviated septum, and to identify factors that might predict such difficulties before surgery. Understanding these factors is important for planning safe anesthesia and reducing risks during the procedure. The study involves adult patients aged 18 to 65 with nasal obstruction due to septal deviation who are undergoing septoplasty under general anesthesia requiring tracheal intubation. Anesthesia will be standardized using specific drugs, and airway management techniques will include using different laryngoscopes and tools if intubation proves difficult. The Cormack-Lehane scale will be used to classify intubation difficulty, and if initial attempts fail, alternative methods including videolaryngoscopy and laryngeal mask airway placement will be considered. Participants will have preoperative airway assessments using the LEMON protocol and the STOP-BANG questionnaire to evaluate OSAS risk. During surgery, monitoring will include heart rate, blood pressure, and oxygen levels. Data collected will include intubation difficulty grade, number of attempts, use of special devices, and ventilation methods. This information will help determine the frequency of difficult intubations and identify predictive factors, contributing to safer airway management in septoplasty patients.

Researchers are evaluating the safety and effectiveness of a drug called Imeroprubart in adults who have Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a condition affecting the nerves. This Phase 2b study is conducted at multiple centers and uses a randomized, double-blind, placebo-controlled design to compare Imeroprubart with a placebo in participants with active CIDP. Participants receive either Imeroprubart or a matching placebo by subcutaneous injection once a week. The treatment is given for 24 weeks during the first period, followed by an extension period of 52 weeks for continued monitoring. Imeroprubart is dosed once weekly by injection under the skin, and the placebo group receives matching injections during the initial 24 weeks. Throughout the study, participants undergo various assessments to monitor their health and response to treatment. Researchers measure the proportion of participants who remain free from disease relapse by Week 24. Safety and efficacy are closely tracked with clinical evaluations and diagnostic tests. The total duration of participation includes the treatment periods and follow-up to observe outcomes and potential side effects.